The macrolide antibiotics market was valued at $5.6 billion in 2022 and is estimated to reach $7.0 billion by 2032, exhibiting a CAGR of 2.3% from 2023 to 2032. Macrolides are a class of antibiotics, used to treat and manage bacterial infections. These antibiotic compounds have a macrocyclic lactone ring attached with deoxy sugars. Erythromycin was the first macrolide antibiotic developed in 1952 and was used in the treatment of infections in patients allergic to penicillin and also in the case of penicillin resistant infections. Other macrolide antibiotics include roxithromycin, clarithromycin, telithromycin, azithromycin, fidaxomicin and others. The FDA has approved the use of these antibiotics in the treatment of various bacterial infections, which increases their demand in the market.
Macrolide antibiotics act by inhibiting bacterial protein synthesis. These compounds bind to the bacterial 50 S ribosomal subunit, causing the cessation of bacterial protein synthesis. After binding, the drug prevents the translation of mRNA, by inhibiting the enzyme peptidyl transferase from adding the subsequent amino acid attached to the tRNA. Erythromycin is the most used antibiotic, followed by azithromycin and clarithromycin. These antibiotics are active against many strains of bacteria such as streptococci, staphylococci, clostridia, corynebacteria, listeria, haemoplhillus, and others. Erythromycin has a narrow spectrum of activity with action against gram-positive and few gram-negative bacteria. On the other hand, clarithromycin and azithromycin are active against gram-negative bacteria such as helicobacter pylori, taxoplasma gondii and others.
Rise in incidences of bacterial infections around the globe is the major factor driving the growth of the macrolide antibiotics market. There is a significant prevalence of bacterial diseases such as skin infections, respiratory tract infections, sextually transmitted bacterial infection, and others. For instance, according to the WHO, there were an estimated 82.4 million new gonorrhoea infections among adults in 2020. Gonorrhoea is a common sexually transmitted infection having the highest incidence among sex workers, transgender women and adolescents. Thus, rise in incidences of such infections boost the demand for macrolide antibiotics, which contributes to the market growth.
However, rise in antimicrobial resistance among the bacterial species causes hindrance to the market growth. Emergence of macrolide resistant bacteria causes difficulty in treatment of severe infections, which may lead to the death of the patient, increase hospital stay, and increase the cost and expenses related to treatment. As the number of infections caused by macrolide resistant bacteria increases, drugs become ineffective for treatment and thus, there is a reduction in use of available macrolide medications. . This may hinder the growth of the macrolide antibiotics market.
However, a rise in antimicrobial resistance for macrolide class of drug is expected to offer lucrative opportunities for market growth during the forecast period. As bacteria are resistant to the available macrolide antibiotics, there is rise in demand for development of new novel macrolide antibiotics that may help overcome the resistance and thus, are effective in the treatment of severe bacterial infections. This increases R&D activities related to the macrolides and thus, is expected to offer lucrative opportunities for market growth in the coming years.
The macrolide antibiotics market is segmented on the basis of drug type, route or administration, indication, distribution channel, and region. On the basis of drug type, the market is segmented into azithromycin, erythromycin, and others. On the basis of route of administration, the market is classified into oral, parenteral, and others. By indication, the market is segmented into respiratory tract infections, skin infections, sexually transmitted infections, gastrointestinal infections, and others. On the basis of distribution channel, the market is segmented into hospital pharmacies, drug stores & retail pharmacies, and online providers.
By region, the market is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of AsiaPacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and Rest of LAMEA). Major players that operate in the market include Abbott Laboratories, Pfizer Inc., Alkem Laboratories Ltd., Merck & Co., Inc., Sun Pharmaceutical Industries Limited, Teva Pharmaceutical Industries Limited, Centurion Healthcare Private Limited, Wellona Pharma, Bristol Laboratories Ltd., and Crescent Pharma Limited.
Macrolide antibiotics act by inhibiting bacterial protein synthesis. These compounds bind to the bacterial 50 S ribosomal subunit, causing the cessation of bacterial protein synthesis. After binding, the drug prevents the translation of mRNA, by inhibiting the enzyme peptidyl transferase from adding the subsequent amino acid attached to the tRNA. Erythromycin is the most used antibiotic, followed by azithromycin and clarithromycin. These antibiotics are active against many strains of bacteria such as streptococci, staphylococci, clostridia, corynebacteria, listeria, haemoplhillus, and others. Erythromycin has a narrow spectrum of activity with action against gram-positive and few gram-negative bacteria. On the other hand, clarithromycin and azithromycin are active against gram-negative bacteria such as helicobacter pylori, taxoplasma gondii and others.
Rise in incidences of bacterial infections around the globe is the major factor driving the growth of the macrolide antibiotics market. There is a significant prevalence of bacterial diseases such as skin infections, respiratory tract infections, sextually transmitted bacterial infection, and others. For instance, according to the WHO, there were an estimated 82.4 million new gonorrhoea infections among adults in 2020. Gonorrhoea is a common sexually transmitted infection having the highest incidence among sex workers, transgender women and adolescents. Thus, rise in incidences of such infections boost the demand for macrolide antibiotics, which contributes to the market growth.
However, rise in antimicrobial resistance among the bacterial species causes hindrance to the market growth. Emergence of macrolide resistant bacteria causes difficulty in treatment of severe infections, which may lead to the death of the patient, increase hospital stay, and increase the cost and expenses related to treatment. As the number of infections caused by macrolide resistant bacteria increases, drugs become ineffective for treatment and thus, there is a reduction in use of available macrolide medications. . This may hinder the growth of the macrolide antibiotics market.
However, a rise in antimicrobial resistance for macrolide class of drug is expected to offer lucrative opportunities for market growth during the forecast period. As bacteria are resistant to the available macrolide antibiotics, there is rise in demand for development of new novel macrolide antibiotics that may help overcome the resistance and thus, are effective in the treatment of severe bacterial infections. This increases R&D activities related to the macrolides and thus, is expected to offer lucrative opportunities for market growth in the coming years.
The macrolide antibiotics market is segmented on the basis of drug type, route or administration, indication, distribution channel, and region. On the basis of drug type, the market is segmented into azithromycin, erythromycin, and others. On the basis of route of administration, the market is classified into oral, parenteral, and others. By indication, the market is segmented into respiratory tract infections, skin infections, sexually transmitted infections, gastrointestinal infections, and others. On the basis of distribution channel, the market is segmented into hospital pharmacies, drug stores & retail pharmacies, and online providers.
By region, the market is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of AsiaPacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and Rest of LAMEA). Major players that operate in the market include Abbott Laboratories, Pfizer Inc., Alkem Laboratories Ltd., Merck & Co., Inc., Sun Pharmaceutical Industries Limited, Teva Pharmaceutical Industries Limited, Centurion Healthcare Private Limited, Wellona Pharma, Bristol Laboratories Ltd., and Crescent Pharma Limited.
Key Benefits For Stakeholders
- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the macrolide antibiotics market analysis from 2022 to 2032 to identify the prevailing macrolide antibiotics market opportunities.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the macrolide antibiotics market segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report includes the analysis of the regional as well as global macrolide antibiotics market trends, key players, market segments, application areas, and market growth strategies.
Additional benefits you will get with this purchase are:
- Quarterly Update and* (only available with a corporate license, on listed price)
- 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
- Free Upcoming Version on the Purchase of Five and Enterprise User License.
- 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
- 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
- Free data Pack on the Five and Enterprise User License. (Excel version of the report)
- Free Updated report if the report is 6-12 months old or older.
- 24-hour priority response*
- Free Industry updates and white papers.
Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)
- Regulatory Guidelines
- Additional company profiles with specific to client's interest
- Additional country or region analysis- market size and forecast
- Expanded list for Company Profiles
- Historic market data
- Key player details (including location, contact details, supplier/vendor network etc. in excel format)
Key Market Segments
By Drug Type
- Azithromycin
- Erythromycin
- Others
By Route of Administration
- Oral
- Parenteral
- Others
By Indication
- Respiratory Tract Infections
- Skin Infections
- Sexually Transmitted Infections
- Gastrointestinal Infections
- Others
By Distribution Channel
- Hospital Pharmacies
- Drug Stores and Retail Pharmacies
- Online Providers
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
- Key Market Players
- Pfizer Inc.
- Teva Pharmaceutical Industries Limited
- Wellona Pharma Private Limited.
- Sun Pharmaceutical Industries Limited
- Bristol Laboratories Ltd.
- Zydus Lifesciences Limited
- Alkem Laboratories Ltd.
- Crescent Pharma Limited
- Merck & Co., Inc.
- Abbott Laboratories
Table of Contents
CHAPTER 1: INTRODUCTION
CHAPTER 2: EXECUTIVE SUMMARY
CHAPTER 3: MARKET OVERVIEW
CHAPTER 4: MACROLIDE ANTIBIOTICS MARKET, BY DRUG TYPE
CHAPTER 5: MACROLIDE ANTIBIOTICS MARKET, BY ROUTE OF ADMINISTRATION
CHAPTER 6: MACROLIDE ANTIBIOTICS MARKET, BY INDICATION
CHAPTER 7: MACROLIDE ANTIBIOTICS MARKET, BY DISTRIBUTION CHANNEL
CHAPTER 8: MACROLIDE ANTIBIOTICS MARKET, BY REGION
CHAPTER 9: COMPETITIVE LANDSCAPE
CHAPTER 10: COMPANY PROFILES
List of Tables
List of Figures
Executive Summary
The macrolide antibiotics market is likely to experience a significant growth rate of 2.3% from 2023-2032 owing to increasing market demand from pharmaceuticals sector.Macrolide antibiotics are the products obtained naturally, which act by inhibiting the synthesis of bacterial protein, thereby limiting the bacterial growth and spread of bacterial infections. Macrolides are used for the treatment of illnesses brought on by gram-positive bacteria. Atypical mycobacterial infections, H. pylori, skin, soft tissue, respiratory, sexually transmitted, and other infections can be successfully treated with macrolides.
Key factors driving the growth of the macrolide antibiotics market are attributed to the rise in incidences of bacterial infections, availability of generic medications and significant demand for macrolides from emerging countries. There is a huge demand for macrolide antibiotics in the developing region owing to high incidences of microbial infections in this region. In addition, emerging countries often have high incidences of infectious diseases due to factors such as poor sanitation, limited access to clean water, and overcrowded living conditions. These infections can be treated with macrolide antibiotics which propels its demand in the healthcare sector.
In addition, macrolide antibiotics are available in generic form with further contributes to the rising demand for these medications. Generic products are easily available at a lower price as compared to other branded medications which can be easily accessible by the people in poor income countries. This affordability factor drives the demand for generic macrolide drugs and expands the market size.
Furthermore, development of novel macrolide antibiotics is anticipated to drive the market growth during the forecast period. Key players are investing on a large scale to develop new products that are effective against antibiotic resistance bacteria, as antimicrobial resistance is one of the major global threats to human beings and the healthcare industry. For instance, in January 2020, Merck announced the U.S. Food and Drug Administration (FDA) approval of New Drug Application (NDA) for DIFICID (fidaxomicin) tablets, for the treatment of Clostridioides difficile-associated diarrhea (CDAD) in children aged six months and older. Such development of novel therapeutics is anticipated to propel the market growth in coming years.
Furthermore, the macrolide antibiotics market is expected to experience significant growth opportunities in developing regions over the next few years. The developing regions are working towards improving their healthcare infrastructure for which they need to set up and expand medical facilities, such as hospitals, clinics and outpatient care centers. This growth in medical facilities creates a need for medical gases, which are needed for patient care and for a variety of medical procedures.
The macrolide antibiotics market is segmented on the basis of drug type, route or administration, indication, distribution channel, and region. On the basis of drug type, the market is segmented into erythromycin, azithromycin, and others. On the basis of route of administration, the market is classified into oral, parenteral, and others. By indication, the market is segmented into respiratory tract infections, skin infections, sexually transmitted infections, gastrointestinal infections, and others. On the basis of distribution channel, the market is segmented into hospital pharmacies, drug stores & retail pharmacies, and online providers.
By region, the market is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and Rest of LAMEA).
The key players profiled in the study include Abbott Laboratories, Pfizer Inc., Alkem Laboratories Ltd., Merck & Co., Inc., Sun Pharmaceutical Industries Limited, Teva Pharmaceutical Industries Limited, Centurion Healthcare Private Limited, Wellona Pharma, Bristol Laboratories Ltd., and Crescent Pharma Limited. The players in the market have been actively engaged in the adoption of various strategies such as product approval and product launch to remain competitive and gain an advantage over the competitors in the market.
For instance, in March 2023, Zydus Lifesciences Limited received the U.S. Food and Drug Administration (USFDA) approval for Erythromycin Tablets USP, 250 mg and 500 mg. It is an antibacterial product and is used to prevent and treat infections in many different parts of the body, including respiratory tract infections, skin infections, diphtheria, intestinal amebiasis, acute pelvic inflammatory disease, Legionnaire's disease and pertussis.
Key Market Insights
By drug type, the Azithromycin segment was the highest revenue contributor to the market and is estimated to reach $4.5 billion by 2032, with a CAGR of 2.3%.By route of administration, the oral segment dominated the global market and is expected to be the fastest-growing segment during the forecast period.
By indication, the respiratory tract infections segment dominated the market in 2022 and is anticipated to be the fastest growing segment during the forecast period.
By distribution channel, the drug stores & retail pharmacies segment dominated the market in 2022, whereas the online providers segment is anticipated to grow at a fastest rate during the forecast period.
Based on region, Asia-Pacific garnered the largest revenue share in 2022 and is anticipated to grow at the highest CAGR during the forecast period.
Companies Mentioned
- Pfizer Inc.
- Teva Pharmaceutical Industries Limited
- Wellona Pharma Private Limited.
- Sun Pharmaceutical Industries Limited
- Bristol Laboratories Ltd.
- Zydus Lifesciences Limited
- Alkem Laboratories Ltd.
- Crescent Pharma Limited
- Merck & Co., Inc.
- Abbott Laboratories
Methodology
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.
LOADING...
